Dementia in focus

CPD
By
Chloe Hava
-

References

  1. Australian Bureau of Statistics. Dementia is Australia’s leading cause of death. Canberra (ACT): Australian Government; 2025. At: https://www.abs.gov.au/media-centre/media-releases/dementia-australias-leading-cause-death
  2. Therapeutic Guidelines. Psychotropic. Melbourne: Therapeutic Guidelines Limited; 2025. At: https://www.tg.org.au
  3. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.
  4. Kepp KP, Robakis NK, Høilund-Carlsen PF, et al. The amyloid cascade hypothesis: an updated critical review. Brain. 2023;146(10):3969-3990.
  5. Khan A, Kalaria RN, Corbett A, et al. Update on vascular dementia. J Geriatr Psychiatry Neurol. 2016;29(5):281-301.
  6. Sin Chin K. Pathophysiology of dementia. Aust J Gen Pract. 2023;52:516-521.
  7. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020;19(2):145-156.
  8. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682.
  9. Therapeutic Guidelines. Dementia. Melbourne: Therapeutic Guidelines Limited; 2025. At: https://www.tg.org.au
  10. Dementia Australia. Types of dementia. At: https://www.dementia.org.au/about-dementia/types-dementia
  11. World Health Organization. Dementia. 2025. At: https://www.who.int/news-room/fact-sheets/detail/dementia
  12. Australian Institute of Health and Welfare. Dementia awareness survey. Canberra (ACT): Australian Government; 2024. At: https://www.aihw.gov.au/reports/dementia/dementia-awareness-survey/contents/attitudes-towards-dementia
  13. Australian Government Department of Health and Aged Care. National dementia action plan 2024–2034. Canberra (ACT): Australian Government; 2025. At: https://www.health.gov.au/our-work/national-dementia-action-plan
  14. Bell S, Bhat R, Brennan S, et al. Clinical practice guidelines for the appropriate use of psychotropic medications in people living with dementia and in residential aged care: summary of recommendations and good practice statements. Parkville (VIC): Monash University; 2022. At: https://www.monash.edu/__data/assets/pdf_file/0005/3657128/240424_Clinical-Pracitcie-Guidelines-for-the-Appropriate-Use-of-Psychotorpic-Medications-in-People-Living-with-Dementia-and-in-Residential-Aged-Care.pdf
  15. Australian Institute of Health and Welfare. Dementia in Australia. Canberra (ACT): Australian Government; 2025. At: https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/deaths-and-disease-burden/deaths-due-to-dementia
  16. Quek HW, Reus X, Lee K, et al. Deprescribing in older people: a clinical practice guideline. Perth (WA): The University of Western Australia; 2025.
  17. Hafez G, Malyszko J, Golenia A, et al. Drugs with a negative impact on cognitive functions (part 2): drug classes to consider while prescribing in CKD patients. Clin Kidney J. 2023;16(12):2378-2392.
  18. LoGiudice D, Smith K, Thomas J, et al. Kimberley Indigenous cognitive assessment tool (KICA): development of a cognitive assessment tool for older Indigenous Australians. Int Psychogeriatr. 2006;18(2):269-280.
  19. Low A, Prats-Sedano MA, McKiernan E, et al. Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia study. Alzheimers Res Ther. 2022;14(1):154.
  20. Corrada MM, Brookmeyer R, Paganini-Hill A, et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010;67(1):114-121.
  21. Berg-Weger M, Stewart DB. Non-pharmacologic interventions for persons with dementia. Mo Med. 2017;114(2):116-119.
  22. Scales K, Zimmerman S, Miller SJ. Evidence-based nonpharmacological practices to address behavioral and psychological symptoms of dementia. Gerontologist. 2018;58(Suppl 1):S88-S102.
  23. Tan E, Hilmer S, Garcia-Ptacek S, et al. Current approaches to the pharmacological treatment of Alzheimer’s disease. Aust J Gen Pract. 2018;47:586-592.
  24. Mok PLH, Carr MJ, Guthrie B, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268.
  25. Australian Medicines Handbook Pty Ltd. Alzheimer’s disease. Adelaide: Australian Medicines Handbook Pty Ltd; 2025. At: https://amhonline.amh.net.au
  26. Waite LM. New and emerging drug therapies for Alzheimer disease. Aust Prescr. 2024;47(3):75-79.
  27. Page AT, Potter K, Clifford R, et al. Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. Intern Med J. 2016;46(10):1189-1197.
  28. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-787.
  29. Barbosa B, Resende EPF, Castilhos RM, et al. Use of anti-amyloid therapies for Alzheimer’s disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol. 2024;18:e2024C002.
  30. Australian Pharmacist. Advancing dementia care in pharmacy. 2025. At: https://www.australianpharmacist.com.au/advancing-dementia-care/
  31. Vassilakopoulou V, Karachaliou CE, Evangelou A, et al. Peptide-based vaccines for neurodegenerative diseases: recent endeavors and future perspectives. Vaccines (Basel). 2021;9(11).
  32. Horgan D, Nobili F, Teunissen C, et al. Biomarker testing: piercing the fog of Alzheimer’s and related dementia. Biomed Hub. 2020;5(3):19-40.
  33. Dementia Australia. Dismantling dementia discrimination. 2022. At: https://www.dementia.org.au/sites/default/files/2023-10/DAW-Dismantling-dementia-discrimination.pdf
  34. Dementia Australia. Dementia and Aboriginal and Torres Strait Islander people. At: https://www.dementia.org.au/dementia-and-aboriginal-and-torres-strait-islander-people
  35. Dementia Australia. Aboriginal and Torres Strait Islander peoples and dementia. At: https://dementia-org.libguides.com/ATSI-peoples-and-dementia
  36. Burnand A, Woodward A, Kantilal K, et al. The potential for clinical pharmacists to support older people with dementia in the community: a qualitative interview study. Br J Clin Pharmacol.
  37. Pharmaceutical Society of Australia. Pharmacists play critical role in dementia care. 2025. At: https://www.psa.org.au/psa-pharmacists-play-critical-role-in-dementia-care/